Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring

Mart Schiefer; Lizza E. L. Hendriks; Dinh Dinh; Ulrich Lalji; Anne-Marie C. Dingemans

doi:10.1016/j.ejca.2017.12.011

Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring

Mart Schiefer, Lizza E. L. Hendriks, Dinh Dinh, Ulrich Lalji, Anne-Marie C. Dingemans

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	92-98
Number of pages	7
Journal	European Journal of Cancer
Volume	91
DOIs	https://doi.org/10.1016/j.ejca.2017.12.011
Publication status	Published - 1 Mar 2018

Keywords

Non-small cell lung cancer
Tyrosine kinase inhibitor
QT interval
Disease flare
Drug monitoring
CELL LUNG-CANCER
1ST-LINE TREATMENT
PHASE-3 TRIAL
OPEN-LABEL
GEFITINIB
ADENOCARCINOMA
DACOMITINIB
INHIBITOR
ERLOTINIB
INTERVAL

Cite this

Schiefer, M., Hendriks, L. E. L., Dinh, D., Lalji, U., & Dingemans, A-M. C. (2018). Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. European Journal of Cancer, 91, 92-98. https://doi.org/10.1016/j.ejca.2017.12.011

@article{beca04c7de2248918c48fdba4bd3f257,

title = "Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring",

keywords = "Non-small cell lung cancer, Tyrosine kinase inhibitor, QT interval, Disease flare, Drug monitoring, CELL LUNG-CANCER, 1ST-LINE TREATMENT, PHASE-3 TRIAL, OPEN-LABEL, GEFITINIB, ADENOCARCINOMA, DACOMITINIB, INHIBITOR, ERLOTINIB, INTERVAL",

author = "Mart Schiefer and Hendriks, {Lizza E. L.} and Dinh Dinh and Ulrich Lalji and Dingemans, {Anne-Marie C.}",

year = "2018",

month = mar

day = "1",

doi = "10.1016/j.ejca.2017.12.011",

language = "English",

volume = "91",

pages = "92--98",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

TY - JOUR

T1 - Current perspective: Osimertinib-induced QT prolongation

T2 - new drugs with new side-effects need careful patient monitoring

AU - Schiefer, Mart

AU - Hendriks, Lizza E. L.

AU - Dinh, Dinh

AU - Lalji, Ulrich

AU - Dingemans, Anne-Marie C.

PY - 2018/3/1

Y1 - 2018/3/1

KW - Non-small cell lung cancer

KW - Tyrosine kinase inhibitor

KW - QT interval

KW - Disease flare

KW - Drug monitoring

KW - CELL LUNG-CANCER

KW - 1ST-LINE TREATMENT

KW - PHASE-3 TRIAL

KW - OPEN-LABEL

KW - GEFITINIB

KW - ADENOCARCINOMA

KW - DACOMITINIB

KW - INHIBITOR

KW - ERLOTINIB

KW - INTERVAL

U2 - 10.1016/j.ejca.2017.12.011

DO - 10.1016/j.ejca.2017.12.011

M3 - Article

VL - 91

SP - 92

EP - 98

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -

Access to Document

10.1016/j.ejca.2017.12.011